Beijing Boao Jingdian Biotechnology Co., Ltd. (hereinafter referred to as “CapitalBio Technology” or the “Company”), a leading provider of genetic testing and biochip technology in China, announced today the completion of a pre-IPO round of financing of RMB 800 million.

CEC Capital Group served as the exclusive financial advisor of CapitalBio Technology in this transaction.

This round was led by Guangzhou Boyi Architectural Design Institute, with an injection of RMB 400 million. Other investors include Sinopec Capital, Meinian Onehealth, New Alliance Capital, Red Horse Investment Group, Xin Ding Capital, and Friend Capital, among others.

The success of this round of financing demonstrates full recognition of CapitalBio Technology’s market-leading position and development potential in the field of genetic testing and biochips by top-tier investors. It also highlights the market-leading capabilities of CEC Capital Group as an investment banking advisor in the field of in-vitro diagnostics.

Proceeds from the latest round will be used to develop new products, expand chip production, further grow the company's pipeline in the fields of reproductive health, infection, and oncology, build its sales and marketing team, and further expand into the overseas market. With the help of this financing, CapitalBio Technology will be able to further consolidate its market-leading position in the field of genetic testing and biochips, and initiate its application for an IPO on the Shanghai STAR Market.

Capitalbio Technology is the industrialization platform of Boao Biological Group Co., Ltd. and Beijing National Engineering Research Center for Biochips. It is the core enterprise in the field of life science of Tsinghua University. At present, Capitalbio Technology's subsidiaries include Beijing Boao Medical Laboratory Co., Ltd., Dongguan Boao Muhua Gene Technology Co., Ltd., Chongqing Boao Xinjing Medical Technology Co., Ltd., and Boao Yihe Health Science and Technology (Beijing) Co., Ltd.

Based on a new generation of biological detection technology, the Company has a complete industrial chain integrating R&D, manufacturing, sales and independent clinical lab services, offering technical support and solutions to organizations focused on domestic and foreign life science research, medical testing, new drug research and development, health management, judicial identification, agriculture and forestry science, and food safety. At the same time, the Company responds to the national health policy of “prevention first” and closely integrates modern medicine with traditional Chinese medicine to create a collection of health products and provide health management, medical rehabilitation and related data.

As the industry leader, Capitalbio Technology is a pioneer in the biochip field in China. It also formulates technical standards for the industry, maintains one of the largest portfolios of related technology patents, and carries the most comprehensive qualification certifications in China. Capitalbio Technology has developed and operates the world's largest proprietary biochip technology platform. It is a member of the National Biochip Standardization Committee, the Beijing National Engineering Research Center for Biochips, and a drafting member of national and industry standards. The Company has obtained more than 300 approved domestic and foreign patents, with a patent conversion rate of nearly 50%.

About CEC Capital Group

Founded in 2000, CEC Capital Group is one of China’s leading investment banks focusing on the three major industries of healthcare, consumer, and TMT. The company is headquartered in Beijing, with offices in Shanghai. Its US affiliate, China eCapital Partners, LLC, has offices in Los Angeles and San Francisco.

In the three years from 2017 to 2019, CEC Capital Group has participated in financing and M&A transactions valued at a total of more than RMB 100 billion. In addition to its investment banking business, CEC Capital Group has been managing an RMB fund and a USD fund since 2014.

CEC Capital Group has the healthcare industry’s largest dedicated investment banking coverage team in China, with comprehensive coverage of the entire ecosystem and a market-leading position in the industry. The firm has advised on the largest number of healthcare-related private capital financing transactions over the past three years among China-based investment banks.